Gilgamesh Pharmaceuticals CEO Jonathan Sporn tells Proactive the New York-based, privately-held group is advancing its slew of psychedelic-focused therapeutics through pre-clinical studies.
Sporn says its orally-active ketamine compound is currently the most advanced of its three therapeutics. Sporn adds the group is currently well-financed to continue its research, however, it will eventually look to hold another round of financing to support its efforts.